Tag Archives: CR845

This Marijuana Stock Could Be 1 Clinical Trial Away From a $1 Billion Valuation

Cara Therapeutics May Be 1 Clinical Trial Away From a $1 Billion Valuation

Cara Therapeutics May Be 1 Clinical Trial Away From a $1 Billion Valuation

If just a single clinical trial works in favor of Cara Therapeutics, it could regain everything it’s recently lost and possibly hit a $1 billion market cap.

Cara Therapeutics Stock Has Lost More Than Half Its Value in 2 Weeks

Cara Therapeutics Stock Has Lost More Than Half Its Value in 2 Weeks

On June 27, Cara Therapeutics (NASDAQ:CARA), a clinical-stage biotech company with a focus on treating chronic pain and pruritus, surged to an all-time intraday high of $28.50 a share. Cara was just $73 million away from joining the $1 billon market cap ranks.

Here’s Why Emerging Marijuana Stock Cara Therapeutics Inc. Surged

Here’s Why Emerging Marijuana Stock Cara Therapeutics Inc. Surged

Shares of Cara Therapeutics Inc., a clinical-stage biotech company with a focus on treating pain and pruritus, rocketed higher by as much as 11% during Wednesday’s trading session after providing an update to its phase 3 trial involving kappa opioid receptor agonist CR845.

: 3 Marijuana Stocks to Buy if You're Leery of Buying Marijuana Stocks

3 Stocks to Buy if You’re Leery of Buying Marijuana Stocks

Although marijuana stocks have skyrocketed in the last couple of years, many investors have been understandably leery of jumping on board. Check out why investors might like these three stocks that don’t fit the mold of most marijuana stocks.


Top